NEW YORK (GenomeWeb News) — Stratagene today said it expects fourth-quarter revenue to be around $24.7 million, or 7 percent better than last year’s pro forma revenue of $23 million for the same period.
The uptick came largely from sales of the company’s QPCR products and reagents, which were up 7 percent, and from allergy diagnostics products, which were up 23 percent, Stratagene said.
However, Stratagene said it expects these increases to be offset by an expected drop in sales of its gene-discovery and cloning products.
Stratagene did not say how much it expects these legacy sales to decrease, but EO Joseph Sorge said the company believes market growth for molecular and clinical diagnostics will “provide sizeable, long-term profitable revenue growth opportunities. …”
The company expects to release final fourth quarter and full year results in early March 2007.
In the fourth quarter of 2005, Stratagene received a one-time payment of $34.1 million from Cambridge Antibody Technology for patent interests, which boosted total revenue to $57.1 million.